You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MCL treatment patterns

Showing 1 - 25 of 4,363
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Disease Registry of Patients With Mantle Cell Lymphoma

Active, not recruiting
  • Mantle Cell Lymphoma
    • Montgomery, Alabama
    • +33 more
    Oct 28, 2022

    Knee Osteoarthritis Trial in Winnipeg, London (Neutral Mechanical Alignment, Anatomical Alignment)

    Active, not recruiting
    • Knee Osteoarthritis
    • Neutral Mechanical Alignment
    • Anatomical Alignment
    • Winnipeg, Manitoba, Canada
    • +1 more
    Sep 26, 2022

    Mantle Cell Lymphoma Trial in United States (R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
    • Basking Ridge, New Jersey
    • +4 more
    Dec 1, 2022

    Mantle Cell Lymphoma Trial in China (400mg of TQB3909 tablets, 600mg of TQB3909 tablets)

    Recruiting
    • Mantle Cell Lymphoma
    • 400mg of TQB3909 tablets
    • 600mg of TQB3909 tablets
    • Beijing, Beijing, China
    • +27 more
    Oct 26, 2023

    Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

    Completed
    • Mantle Cell Lymphoma
      • Seoul, Korea, Republic of
        81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
      Oct 21, 2020

      Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

      Recruiting
      • Recurrent Mantle Cell Lymphoma
      • Refractory Mantle Cell Lymphoma
      • Biospecimen Collection
      • Follow-Up
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022

      Mantle Cell Lymphoma Trial (drug, biological, other, procedure)

      Not yet recruiting
      • Mantle Cell Lymphoma
      • (no location specified)
      Jul 26, 2023

      Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (brexucabtagene autoleucel, Cyclophosphamide, Fludarabine)

      Active, not recruiting
      Has Results
      • Relapsed/Refractory Mantle Cell Lymphoma
      • brexucabtagene autoleucel
      • +3 more
      • Gilbert, Arizona
      • +31 more
      Jan 26, 2023

      Lymphoma Trial in Beijing, Shanghai City, Seoul (Obinutuzumab, Glofitamab, Rituximab)

      Recruiting
      • Lymphoma
      • Beijing, China
      • +2 more
      Oct 12, 2023

      Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma Trial in India (Acalabrutinib capsule)

      Active, not recruiting
      • Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
      • Acalabrutinib capsule
      • Ahmedabad, India
      • +12 more
      Feb 2, 2023

      Untreated Mantle Cell Lymphoma Trial in Suzhou (zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance)

      Recruiting
      • Untreated Mantle Cell Lymphoma
      • zanubrutinib and rituximab
      • +2 more
      • Suzhou, Jiangsu, China
        the First Affiliated Hospital of Soochow University
      Aug 16, 2022

      Intubation Complication, Cardiopulmonary Arrest Trial in Lódz (IntuBrite intubation, Macintosh laryngoscope)

      Completed
      • Intubation Complication
      • Cardiopulmonary Arrest
      • IntuBrite intubation
      • Macintosh laryngoscope
      • Łódź, Poland
        Medical University of Lodz, Poland
      Nov 2, 2022

      Relapsed/Refractory Mantle Cell Lymphoma Trial in Worldwide (Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel)

      Recruiting
      • Relapsed/Refractory Mantle Cell Lymphoma
      • Gilbert, Arizona
      • +40 more
      Jan 6, 2023

      Mantle Cell Lymphoma Trial (Zanubrutinib, Rituximab)

      Not yet recruiting
      • Mantle Cell Lymphoma
      • (no location specified)
      Nov 22, 2022

      Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma Trial in Hangzhou (ZR2 RDHAP)

      Recruiting
      • Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
      • ZR2 RDHAP
      • Hangzhou, Zhejiang, China
        Zhejiang Cancer Hospital
      Aug 8, 2023

      Mantle Cell Lymphoma (MCL) Trial in Japan (Ibrutinib, Venetoclax)

      Active, not recruiting
      • Mantle Cell Lymphoma (MCL)
      • Nagoya-shi, Aichi, Japan
      • +11 more
      Apr 4, 2022

      "Don't Eat me" Signal in Hematological Malignancies: CD24 as New

      Recruiting
      • Mantle-cell Lymphoma
      • B Cell Chronic Lymphocytic Leukemia
        • Monza, MB, Italy
          Andrea Aroldi
        May 24, 2023

        Mantle Cell Lymphoma Trial in China (High dose, Low dose)

        Not yet recruiting
        • Mantle Cell Lymphoma
        • High dose
        • Low dose
        • Bengbu, Anhui, China
        • +20 more
        Jul 28, 2023

        B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)

        Recruiting
        • B-cell Non-Hodgkin Lymphoma
        • Mosunetuzumab (IV)
        • +4 more
        • Birmingham, Alabama
        • +28 more
        Jan 6, 2023

        Mantle Cell Lymphoma Trial in Duarte, Ann Arbor, Columbus (Venetoclax, Lenalidomide, Rituximab)

        Active, not recruiting
        • Mantle Cell Lymphoma
        • Duarte, California
        • +2 more
        Oct 18, 2022

        Mantle Cell Lymphoma Trial in Germany, Italy, Switzerland (Ibrutinib, bortezomib)

        Terminated
        • Mantle Cell Lymphoma
        • Mainz, Germany
        • +18 more
        Feb 24, 2022

        Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)

        Not yet recruiting
        • Lymphoma
        • Mantle Cell Lymphoma
        • Houston, Texas
          M D Anderson Cancer Center
        Aug 10, 2022

        MDS (MDS) Trial in United States (Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine)

        Completed
        • Myelodysplastic Syndromes (MDS)
        • Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
        • Chicago, Illinois
        • +11 more
        Apr 4, 2022

        Hematologic Malignancies Trial in Worldwide (Nemtabrutinib)

        Recruiting
        • Hematologic Malignancies
        • Torrance, California
        • +51 more
        Jan 12, 2023

        Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II

        Active, not recruiting
        • Phase I: Relapsed or Refractory B-cell Malignancies
        • +2 more
        • Beijing, China
        • +22 more
        Dec 8, 2022